SAMRAT PHARMACHEM
|
SAMRAT PHARMACHEM Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 |
| CEPS(Rs) | 25.14 | 9.09 | 55.91 | 57.54 | 18.86 |
| DPS(Rs) | 1.00 | 1.00 | 1.00 | 1.00 | - |
| Book NAV/Share(Rs) | 232.39 | 210.37 | 204.37 | 151.54 | 95.92 |
| Tax Rate(%) | 28.06 | 14.19 | 26.19 | 27.19 | 27.38 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 3.58 | 0.87 | 7.70 | 10.93 | 4.24 |
| EBIT Margin(%) | 3.69 | 1.14 | 7.65 | 10.95 | 4.22 |
| Pre Tax Margin(%) | 3.46 | 0.90 | 7.25 | 10.64 | 3.59 |
| PAT Margin (%) | 2.49 | 0.77 | 5.35 | 7.75 | 2.61 |
| Cash Profit Margin (%) | 2.72 | 1.00 | 5.56 | 8.02 | 2.85 |
| Performance Ratios | |||||
| ROA(%) | 5.85 | 1.81 | 16.53 | 24.20 | 9.22 |
| ROE(%) | 10.40 | 3.38 | 30.25 | 44.95 | 19.77 |
| ROCE(%) | 13.61 | 4.13 | 34.91 | 52.33 | 23.90 |
| Asset Turnover(x) | 2.35 | 2.36 | 3.09 | 3.12 | 3.53 |
| Sales/Fixed Asset(x) | 17.08 | 17.13 | 19.95 | 15.35 | 16.07 |
| Working Capital/Sales(x) | 5.32 | 6.10 | 6.77 | 6.54 | 10.22 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.06 | 0.06 | 0.05 | 0.07 | 0.06 |
| Receivable days | 80.32 | 78.39 | 55.96 | 63.02 | 54.31 |
| Inventory Days | 37.46 | 34.48 | 26.40 | 19.60 | 26.94 |
| Payable days | 59.00 | 53.71 | 36.30 | 39.45 | 45.34 |
| Valuation Parameters | |||||
| PER(x) | 13.59 | 47.64 | 6.89 | 8.72 | 7.88 |
| PCE(x) | 12.44 | 36.67 | 6.64 | 8.42 | 7.21 |
| Price/Book(x) | 1.35 | 1.59 | 1.82 | 3.20 | 1.42 |
| Yield(%) | 0.32 | 0.30 | 0.27 | 0.21 | - |
| EV/Net Sales(x) | 0.37 | 0.36 | 0.39 | 0.64 | 0.27 |
| EV/Core EBITDA(x) | 9.49 | 26.40 | 4.98 | 5.73 | 5.29 |
| EV/EBIT(x) | 10.07 | 31.73 | 5.11 | 5.87 | 5.60 |
| EV/CE(x) | 1.30 | 1.39 | 1.48 | 1.69 | 0.84 |
| M Cap / Sales | 0.34 | 0.37 | 0.37 | 0.68 | 0.23 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.52 | -9.36 | 40.09 | 23.87 | 30.24 |
| Core EBITDA Growth(%) | 190.99 | -84.21 | -1.87 | 172.36 | 26.79 |
| EBIT Growth(%) | 229.27 | -86.50 | -2.11 | 181.60 | 27.46 |
| PAT Growth(%) | 228.87 | -87.00 | -3.23 | 222.22 | 25.88 |
| EPS Growth(%) | 228.87 | -87.00 | -3.23 | 222.22 | 25.88 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.14 | 0.13 | 0.30 | 0.16 | 0.30 |
| Current Ratio(x) | 2.08 | 1.82 | 1.86 | 1.91 | 1.73 |
| Quick Ratio(x) | 1.32 | 1.45 | 1.25 | 1.58 | 1.31 |
| Interest Cover(x) | 15.67 | 4.67 | 19.29 | 35.99 | 6.75 |
| Total Debt/Mcap(x) | 0.10 | 0.08 | 0.16 | 0.05 | 0.21 |
Compare Financial Ratios of peers of SAMRAT PHARMACHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SAMRAT PHARMACHEM | ₹70.7 Cr | 11.1% | 2.8% | -37% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,615.0 Cr | 4% | -4.9% | -2.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,943.0 Cr | 1.1% | -9.3% | 9.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹133,336.0 Cr | -1.3% | -3.7% | 24% | Stock Analytics | |
| CIPLA | ₹107,499.0 Cr | 1.5% | -9.3% | -7.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,590.0 Cr | 5% | -0.1% | 3.3% | Stock Analytics | |
SAMRAT PHARMACHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SAMRAT PHARMACHEM | 11.1% |
2.8% |
-37% |
| SENSEX | 3.5% |
-1.7% |
7.8% |
You may also like the below Video Courses
